ISO 14155:2026 Updates and Changes

ISO 14155:2026, Clinical Investigation of Medical Devices for Human Subjects – Good Clinical Practice, is now the global benchmark for medical device clinical investigations, replacing ISO 14155:2020 and redefining expectations for study design, conduct, and reporting. 

While the previous edition prioritized alignment with EU MDR and ICH-GCP principles, the 2026 version addresses practical implementation gaps that emerged during the early years of MDR enforcement. Additionally, ISO 14155:2026 aims to move away from paperwork compliance toward risk-based thinking and statistical rigor.

Most importantly, the 2026 version updates will be immediately applicable — unlike many ISO standards that offer a 3-year transition period. If you have a trial starting in 2026, it must reflect these changes to satisfy notified bodies and regulatory agencies.

Update your library and start implementing this new standard. Purchase ISO 14155:2026 in PDF and print formats.

Key Changes

Risk Management Evolution (Annex H & Core Text)

The 2020 version introduced ISO 14971 (Medical Devices — Application of Risk Management to Medical Devices) principles into clinical trials, but many found the transition confusing. The 2026 update provides much-needed clarification. Updates to the Core Text and Annex H also move away from check-the-box compliance and toward applied risk management that separates the device’s technical risks from the trial’s procedural risks. 

This includes:

• Device Risk vs. Procedure Risk: The standard now distinguishes between risks caused by the device itself (which require full ISO 14971 methodology) and risks caused by non-routine clinical procedures required by the study protocol (which now only require a descriptive risk assessment).
• Sample Size Sensitivity: Risk assessments must now be specifically evaluated against the study’s exact sample size and population, acknowledging that adverse event rates in a trial can differ significantly from broader post-market use.
• Regional Variance: For multi-country studies, sponsors must now document differences in routine clinical practices to ensure risk assessments remain valid across different healthcare systems.

Formalization of Clinical Events Committees (CECs)

While CECs have been used by sophisticated manufacturers for years, ISO 14155:2026 formally introduces them into the standard. For the first time, the standard includes a dedicated section and formal requirements for CECs to ensure data consistency. 

In multi-site trials, doctors often categorize the same event differently. The 2026 update mandates a more structured approach to using independent experts to adjudicate these events. If a CEC is established, sponsors must now formally document the independence requirements, potential conflicts of interest, and mitigation of bias.

Data Monitoring Committees (DMC) 

In the 2020 version, DMCs were encouraged but somewhat discretionary. In the 2026 update, this is no longer the case. If a sponsor chooses not to use a DMC, they must now provide a formal, documented justification for its absence in the Clinical Investigation Plan.  When DMCs are present, they must explicitly confirm the conditions under which a study would be suspended or stopped before the study begins.

The update also synchronizes the flow of data between the sponsor and the DMC, explicitly linking DMCs to the ongoing risk-benefit assessment. They must be provided with unblinded safety data in a specific format to allow for near real-time monitoring. This means that manufacturers must upgrade their data management systems to ensure they can provide the DMC with clean, frequent data exports without compromising the blinding of the internal study team.

Advanced Statistical Frameworks (Annex K)

The introduction of Annex K (Advanced Statistical Frameworks) in ISO 14155:2026 is a game-changer for manufacturers because it moves beyond traditional frequentist statistics. Annex K provides a formal roadmap to use more sophisticated, and often more efficient, mathematical models to prove safety and performance.

These statistical details include:

• Estimand Framework: The update introduces the estimand concept — a structured framework for defining exactly what the clinical question is and how intercurrent events (like a patient switching medications or dropping out) impact the final analysis.
• Missing Data Strategies: Requirements for handling missing data have been tightened, requiring a more proactive investigation planning rather than fixing it in post-analysis.

Annex K will have a big impact because it allows manufacturers to be smarter, not just bigger. If your clinical team is still using 20th-century statistics, you are likely overspending on your trials and carrying more regulatory risk than your competitors who adopt the ISO 14155:2026 frameworks. 

Operational & Ethical Refinements

The operational and ethical refinements in ISO 14155:2026 reflect a shift toward social responsibility and digital maturity. These refinements are a direct response to the logistical failures and ethical scrutiny seen in the global clinical landscape over the last five years. They impact site selection, patient retention, and the legal defensibility of your clinical data.

This includes refinements such as:

• Decentralized Clinical Trials and Remote Monitoring: ISO 14155:2026 finally codifies the shift toward hybrid and decentralized trial models by providing clear requirements for off-site data collection, including wearable integrations and the remote monitoring of source documents. As a result, manufacturers can now recruit from a broader geographic pool, rather than being tethered to a limited pool of academic centers. This speeds up recruitment (the primary cause of trial delays) and ensures that the data collected via remote sensors is considered regulatory grade during an audit.

• Vulnerable Populations and Informed Consent: The 2026 version tightens the ethical requirements around vulnerable populations such as children, or those with cognitive impairments. The change introduces more rigorous standards for informed consent in digital formats (e-consent) and mandates more robust assent processes for minors. As ethics committees become increasingly strict, the 2026 refinements ensure your trial doesn’t get stuck in the approval phase.

• Data Integrity and Cyber-Safety: While previous versions focused on data accuracy, the 2026 update elevates cybersecurity as an ethical obligation to the patient. Manufacturers are now explicitly responsible for the encryption and privacy of patient data, particularly when using cloud-based electronic data capture systems — making data breaches a violation of good clinical practices.

Some manufacturers may view ethical refinements as an administrative burden. However, these are essential elements to market access. Archaic trials that are paper-based, non-diverse, or purely site-centric will likely be viewed as low-quality by modern regulators, potentially requiring expensive secondary and tertiary studies to fully cover all aspects. 

What Does This Mean For The Industry?

ISO 14155:2026 marks a significant evolution in good clinical practice for medical devices. For manufacturers, this means a shift toward higher statistical rigor, tighter safety governance, and a more nuanced approach to risk. This new standard is more than a documentation update, it’s an industry shift towards stronger clinical strategy. While auditors will continue to review the trial’s process, they will also focus on the reasoning behind key decisions and they will evaluate whether the approach is scientifically and clinically justified. 

The lack of an official transition period for this standard signals that these changes were already highly necessary throughout the industry. New studies are expected to align with these requirements.

If you’re working on medical device compliance under MDR, clinical investigations, or post-market studies, this standard will directly impact your next submission and audit outcome.

Takeaway

ISO 14155:2026 marks the new global benchmark for medical device clinical investigations, shifting the focus from paperwork compliance toward risk-based thinking and statistical rigor. Manufacturers who act early — upgrading data management systems, formalizing governance (CECs/DMCs), and adopting advanced statistical frameworks (Annex K) — will be far better positioned to satisfy notified bodies and demonstrate that their clinical strategy is scientifically and clinically justified in upcoming audits.

Update your library and start implementing this new standard. Purchase ISO 14155:2026 in PDF and print formats.

Nimonik — One Platform to Manage Your Requirements

Nimonik aggregates standards from 90+ publishers, including ISO, ASTM, ASCE, CSA, IEEE, API, IPC, and BSI — and regulations across 600+ jurisdictions. As a result, Nimonik provides broad coverage and convenience, allowing medical device teams to track and manage obligations in one easy location. If you need custom lists, complete with historical updates, and robust workflow tools, Nimonik is the ideal choice.